How much does a box of domestically produced Venetoclax/Venetoclax tablets cost?

The original drug Venetoclax was approved by the State Food and Drug Administration in 2020 and was sold in China under the name VENCLEXTA. It has also been included in Class B medical insurance and is only available for reimbursement to eligible patients. It is understood that there is no relevant domestic pharmaceutical factory producing Venetoclax, and it may be in the clinical trial stage. At some point in the future, domestically produced Venetoclax may be put on the market.

Veneclase is aBCL-2 inhibitor that can be used to treat chronic lymphocytic leukemia (CLL), small cell lymphoma (SCL) or acute myeloid leukemia (AML). Venetoclax selectively targets BCL2 and has proven to have a controllable safety profile and can induce rapid and effective apoptosis in CLL cells. This is an oral tablet that is taken once daily with an initial dose escalation to reduce the incidence of side effects such as tumor lysis syndrome (TLS). Neutropenia, nausea, diarrhea, and fatigue are common side effects.

The original drug Venekra which is domestically marketed and included in the medical insurance, the common specification is 100mg*14 tablets per box, may cost around 2,000 yuan, while the Turkish version of the original drug sold overseas, the specification 100mg*112 tablets per box, costs more than 10,000 yuan (the price may fluctuate due to exchange rates). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).